{
    "id": 27384,
    "fullName": "TBXT positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "T positive indicates the presence of T gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6862,
        "geneSymbol": "TBXT",
        "terms": [
            "TBXT",
            "SAVA",
            "T",
            "TFT"
        ]
    },
    "variant": "positive",
    "createDate": "01/09/2018",
    "updateDate": "01/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12668,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GI-6301 demonstrated safety and preliminary efficacy, induced brachyury-specific T-cell immune responses in 54% (14/31) of patients with solid tumors, resulted in disease control in 2 chordoma patients and prolonged stable disease in a patient with colorectal carcinoma (PMID: 26130065).",
            "molecularProfile": {
                "id": 28829,
                "profileName": "TBXT positive"
            },
            "therapy": {
                "id": 6570,
                "therapyName": "GI-6301",
                "synonyms": null
            },
            "indication": {
                "id": 2602,
                "name": "chondroma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10573,
                    "pubMedId": 26130065,
                    "title": "Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12667,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GI-6301 demonstrated safety and preliminary efficacy, induced brachyury-specific T-cell immune responses in 54% (14/31) of patients with solid tumors, resulted in disease control in 2 chordoma patients and prolonged stable disease in a patient with colorectal carcinoma (PMID: 26130065).",
            "molecularProfile": {
                "id": 28829,
                "profileName": "TBXT positive"
            },
            "therapy": {
                "id": 6570,
                "therapyName": "GI-6301",
                "synonyms": null
            },
            "indication": {
                "id": 80199,
                "name": "colorectal carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10573,
                    "pubMedId": 26130065,
                    "title": "Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12666,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GI-6301 demonstrated safety and preliminary efficacy, induced brachyury-specific T-cell immune responses in 54% (14/31) of patients with solid tumors, resulted in disease control in 2 chordoma patients and prolonged stable disease in a patient with colorectal carcinoma (PMID: 26130065).",
            "molecularProfile": {
                "id": 28829,
                "profileName": "TBXT positive"
            },
            "therapy": {
                "id": 6570,
                "therapyName": "GI-6301",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10573,
                    "pubMedId": 26130065,
                    "title": "Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26130065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28829,
            "profileName": "TBXT positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}